Oxford Bioscience Partners Promotes Dr. Douglas Fambrough to General Partner

Business Wire, Sept 19, 2007

BOSTON -- Oxford Bioscience Partners is pleased to announce that Dr. Douglas Fambrough has been promoted to the position of General Partner. Dr. Fambrough has been involved with a series of Oxford portfolio company investments that have created value both for investors as well as for society at large through the advancement of pharmaceutical research and development. These investments are exemplars of Oxford's commitment to the profitable advancement of innovation in biotechnology through cutting-edge technology.

Dr. Fambrough led the investment in RNA interference pioneer Sirna Therapeutics, acquired by Merck & Co., Inc. for $1.1 billion in 2006. He was also actively involved with Oxford's investment in ultra-high-throughput DNA sequencing equipment company Solexa, Inc., which was sold to Illumina, Inc. for approximately $550 million in 2007.

Dr. Fambrough joined Oxford Bioscience Partners in January 2000 as an Associate. He was subsequently promoted to Principal in 2001, and to Partner in 2005. Prior to joining Oxford, Dr. Fambrough was a genomic scientist with the Whitehead/MIT Center for Genome Research (now known as the Broad Institute) in Cambridge, MA. He graduated from Cornell University and received his PhD in genetics from the University of California, Berkeley.

ABOUT OXFORD BIOSCIENCE PARTNERS

Oxford Bioscience Partners (OBP), established in 1992, is a venture capital firm that provides equity financing and management assistance to emerging, entrepreneurial-driven companies within the life sciences and healthcare sectors. Experienced partners, who bring together deep domain knowledge in life sciences, have established a proven track record of identifying, validating and backing emerging trends and technologies. While willing to consider an investment in a company at almost any stage, OBP brings unique value and expertise to early-stage situations. With approximately $1B of committed capital under management, OBP has invested in over 140 life science companies worldwide, and has successfully leveraged the extensive research, operating, and financial expertise and experience of its team of investment professionals. www.oxbio.com